文章名稱引用次數(shù)

• Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point16
• On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies12
• Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond11
• Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?8
• Some statistical considerations in the clinical development of cancer immunotherapies8
• Propensity-score-based priors for Bayesian augmented control design7
• Effect of heteroscedasticity between treatment groups on mixed-effects models for repeated measures6
• Propensity score matched augmented controls in randomized clinical trials: A case study6
• Better decision making in drug development through adoption of formal prior elicitation5
• BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes5